|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4,465.00 KRW | +0.34% |
|
-6.49% | -34.53% |
| 12-09 | GC Genome Study Identifies 'Confounders' Interfering with Cancer Signals to Improve Liquid Biopsy Accuracy | CI |
| 12/06/25 | GC Genome Shares Decline Nearly 3% After Strong Kosdaq Debut | MT |
Business description: GC Genome Corporation

Executive Committee: GC Genome Corporation
| Manager | Title | Age | Since |
|---|---|---|---|
Chang-Seok Gi
CEO | Chief Executive Officer | 57 | 25/03/2020 |
Sang-Hun Jeong
DFI | Director of Finance/CFO | 50 | 26/03/2025 |
Seu-Nga Hyun
AUD | Comptroller/Controller/Auditor | 45 | 28/03/2024 |
Eun-Hae Jo
PRN | Corporate Officer/Principal | 52 | - |
Composition of the Board of Directors: GC Genome Corporation
| Director | Title | Age | Since |
|---|---|---|---|
Sang-Uk Kim
BRD | Director/Board Member | 57 | 29/03/2023 |
Company details: GC Genome Corporation

Medical & Diagnostic Laboratories
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +0.34% | -6.49% | -49.94% | - | 70.95M | ||
| -0.08% | -3.06% | +72.37% | +450.16% | 39.05B | ||
| -0.36% | -2.88% | +10.36% | +29.57% | 22.61B | ||
| +0.33% | -1.69% | -21.23% | -40.38% | 7.39B | ||
| -0.84% | -7.45% | +10.94% | +101.15% | 4.94B | ||
| +0.69% | +6.21% | +18.09% | +50.19% | 3.03B | ||
| -2.22% | -4.57% | -24.23% | +829.02% | 1.85B | ||
| +0.85% | -1.86% | +98.19% | -17.56% | 1.85B | ||
| -1.78% | +6.32% | +33.20% | -20.94% | 1.79B | ||
| +4.57% | +18.53% | -3.33% | -64.74% | 1.85B | ||
| Average | +0.15% | +0.24% | +14.44% | +146.27% | 8.44B | |
| Weighted average by Cap. | -0.08% | -2.29% | +37.89% | +236.44% |
Sector
Annual profits - Rate of surprise
- Stock Market
- Stocks
- A340450 Stock
- Company GC Genome Corporation
Select your edition
All financial news and data tailored to specific country editions

















